Edition:
United Kingdom

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

9.00USD
4:57pm BST
Change (% chg)

$8.25 (+1,101.60%)
Prev Close
$0.75
Open
$11.20
Day's High
$12.76
Day's Low
$8.61
Volume
583,202
Avg. Vol
5,492
52-wk High
$20.50
52-wk Low
$5.80

Chart for

About

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $23.88
Shares Outstanding(Mil.): 13.92
Dividend: --
Yield (%): --

Financials

  CLRB.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -1.24 -- --
ROI: -103.68 15.07 14.61
ROE: -105.20 16.60 16.34

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer

* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER

04 Apr 2018

BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

27 Mar 2018

BRIEF-Cellectar Reports 2017 Financial Results

* CELLECTAR REPORTS 2017 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

21 Mar 2018

BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma

* CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA

19 Mar 2018

BRIEF-Cellectar Receives USPTO Notice Of Allowance For Patent Covering Use Of CLR 131 In Multiple Myeloma

* CELLECTAR RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING USE OF CLR 131 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

07 Feb 2018

Earnings vs. Estimates